HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Gain Therapeutics (NASDAQ:GANX) and maintained a $10 price target.
August 31, 2023 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Gain Therapeutics, maintaining a $10 price target.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Gain Therapeutics. The maintained price target of $10 indicates the firm's continued confidence in the stock's potential, which could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100